Q32 Bio (QTTB) Change in Accured Expenses (2017 - 2026)

Q32 Bio has reported Change in Accured Expenses for 10 years, with the latest figure at -$476000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 78.69% year-over-year to -$476000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.6 million (up 79.69% YoY), and the FY2025 full-year result was -$3.3 million, up 56.86% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$476000.0, down from $306000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $6.6 million in Q2 2022, with the low at -$5.0 million in Q1 2022.
• Average Change in Accured Expenses over 5 years is -$229470.6, with a median of -$889000.0 recorded in 2025.
• Year-over-year, Change in Accured Expenses soared 172.56% in 2022 and slumped 194.19% in 2024.
• Tracing QTTB's Change in Accured Expenses over 5 years: stood at $1.7 million in 2022, then surged by 34.42% to $2.3 million in 2023, then plunged by 143.37% to -$1.0 million in 2024, then surged by 130.06% to $306000.0 in 2025, then slumped by 255.56% to -$476000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$476000.0 (Q1 2026), $306000.0 (Q4 2025), and -$511000.0 (Q3 2025), per Business Quant data.

Peer Comparison